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Abstract Humanized mouse models provide a unique
opportunity to study human immune cells in vivo, but
traditional models have been limited to the evaluation of
non-specific T-cell interactions due to the absence of
antigen-presenting cells. In this study, immunodeficient
NOD/SCID/IL2r-γ
null (NSG) mice were engrafted with
human peripheral blood lymphocytes alone or in combina-
tion with donor-matched monocyte-derived dendritic cells
(DC) to determine whether antigen-specific T-cell activa-
tion could be reconstituted. Over a period of 3 weeks,
transferred peripheral blood lymphocytes reconstituted the
spleen and peripheral blood of recipient mice with
predominantly human CD45-positive lymphocytes. Ani-
mals exhibited a relatively normal CD4/CD8 ratio (average
1.63:1) as well as reconstitution of CD3/CD56 (averaging
17.8%) and CD20 subsets (averaging 4.0%). Animals
reconstituted with donor-matched CD11c+ DC also dem-
onstrated a CD11c+ population within their spleen, repre-
senting 0.27% to 0.43% of the recovered human cells with
concurrent expression of HLA-DR, CD40, and CD86.
When immunized with adenovirus, either as free
replication-incompetent vector (AdV) or as vector-
transduced DC (DC/AdV), there was activation and
expansion of AdV-specific T-cells, an increase in Th1
cytokines in serum, and skewing of T-cells toward an
effector/memory phenotype. T-cells recovered from animals
challenged with AdV in vivo proliferated and secreted a
Th1-profile of cytokines in response to DC/AdV challenge
in vitro. Our results suggest that engrafting NSG mice with
a combination of lymphocytes and donor-matched DC can
reconstitute antigen responsiveness and allow the in vivo
assessment of human immune response to viruses,
vaccines, and other immune challenges.
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Introduction
While inbred strains of conventional and genetically
modified mice have provided an unparalleled opportunity
to examine the process of antigen presentation and the
characteristics of adaptive T-cell immunity, translating these
findings into new approaches for human immunotherapy
has proven problematic (Mestas and Hughes 2004; Ju et al.
2010). Responses to cytokine therapy, vaccines, gene
therapy, adjuvants, and adoptive cell transfers that are
reproducible and robust in the mouse are often rare when
translated into human clinical trials. This is not surprising
given that human dendritic cells (DC) are distinctively
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interest, the major histocompatibility complex (MHC)
repertoire, toll-like receptor expression, cytokine responses,
and many other features. Genetic diversity is also a major
factor, as are the susceptibility and prior exposure to many
human pathogens and immune challenges (Mestas and
Hughes 2004; Zaiss et al. 2009). Even transgenic animals
that express a human MHC haplotype or spontaneously
develop organ-specific tumors have not proven to be
predictive of integrated human immune responses (Pascolo
et al. 1997).
One approach for bridging the gap between mouse
models and human clinical trials has been to develop
humanized mice—immunodeficient strains which permit
the engraftment and expansion of human immune cells in
vivo (Shultz et al. 2007; Pearson et al. 2008). A variety of
different humanized mouse models have been developed
and fall into two distinct categories: (1) those with a slow
but more extensive immune reconstitution resulting from
stem cell transfer (Lapidot et al. 1992; Greiner et al. 1998;
Ito et al. 2002) or (2) those with rapid reconstitution based
on the transfer of fully differentiated human peripheral
blood cells (Mosier et al. 1988; Hesselton et al. 1995; May
et al. 2005). We have focused on the latter, not only for the
speed of the reconstitution but for the prospect that the
reconstituted immune system would reflect the immuno-
logic memory of the human donor. For these studies,
immunodeficient NOD/SCID-IL2rγ
null (NSG) mice, which
lack the γ-chain of the IL-2 receptor in addition to the
NOD/SCID background, were chosen (Ishikawa et al.
2005; Shultz et al. 2005). NSG mice lack high affinity
receptors for interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and
IL-21. As a result of this ineffective cytokine signaling,
these mice completely lack functional T-cells, B-cells, NK
cells, macrophages, and DC and allow nearly complete
immune reconstitution by engrafted human cells (Ishikawa
et al. 2005; Shultz et al. 2005). We hypothesized that
humanized NSG animals, when reconstituted with both
peripheral blood lymphocytes (PBL) and with donor-
matched antigen presenting DC, would allow us to examine
the process of human antigen presentation and the
activation of antigen-specific T-cells as it occurs in vivo,
in the context of the immunologic repertoire of the human
donor. In these studies, we have used a replication-
incompetent serotype-5 adenoviral vector (AdV) as the
antigen. Human exposure to adenovirus and the develop-
ment of anti-viral memory T-cell responses occurs with a
high frequency in the adult population (Olive et al. 2001;
Roth et al. 2002). As predicted, only human peripheral
blood lymphocyte (huPBL)-NSG mice that were reconsti-
tuted with both PBL and DC demonstrated AdV-specific T-
cell proliferation and cytokine production. Furthermore, the
characteristics of the AdV-specific response recapitulated
those of the originally implanted PBL. This model should
provide a rapid and highly flexible system for studying the
activation of human antigen-specific immunity and provide
a novel platform for vaccine development and testing, as
well as for the study of interactions between antigen-
specific immunity and a variety of host challenges such as
viral exposures (including HIV), tumors, and systemic drug
effects.
Materials and methods
Animals
Six- to 8-week-old NSG mice were obtained from The
Jackson Laboratories (Bar Harbor, ME, USA) and housed
at the UCLA Mouse/Human Chimera Core Facility under
laminar flow conditions with all food, water (acidified),
caging, and bedding autoclaved before use. No antibiotics
were administered. All procedures were approved by the
UCLA Animal Research Committee.
Culture media and reagents
Cells were cultured in complete medium composed of
RPMI 1640 (Mediatech, Manassas, VA, USA) supple-
mented with 10% heat-inactivated human AB serum
(Omega Scientific, Tarzana, CA, USA), penicillin–
streptomycin–fungizone (Invitrogen, Carlsbad, CA,
USA), and 10 mM HEPES (Sigma Chemical, St. Louis,
MO, USA). Monoclonal antibody (mAb) combinations
used for the enrichment of T-and B-cells (anti-CD14, anti-
CD16, and anti-CD25) and DC (anti-CD3, anti-CD16,
and anti-CD19) by negative depletion were obtained from
BD Biosciences (San Jose, CA, USA). Anti-mouse
Ig-conjugated immunomagnetic beads were from Invitro-
gen (M450 Dynabeads; Carlsbad, CA, USA).
Fluorochrome-conjugated mAbs against CD3, CD4, CD8,
CD11c, CD86, and HLA-DR were obtained from BD
Biosciences; anti-CD127 and anti-GITR from eBiosciences
(San Diego, CA, USA); and anti-CD25 from BioLegend
(San Diego, CA, USA). T-cell proliferation in vitro was
evaluated using carboxyfluorescein diacetate, succinimidyl
ester (CFSE; Vybrant CFDA SE Cell Tracer Kit, Invitrogen-
Molecular Probes, Eugene, OR, USA).
Adenoviral vectors
A replication-deficient adenoviral vector (AdV) expressing
green fluorescent protein (GFP) and modified to express an
additional Arg-Gly-Asp peptide sequence in the HI loop
region of their fiber knob was obtained from Mizuguchi et
J Neuroimmune Pharmacol (2011) 6:148–157 149al. (2001) (AdV-GFP). A replication-deficient adenoviral
vector with a matching CMV promoter but without an
inserted transgene sequence (AdV-RR5) was also used as
previously described (Roth et al. 2002). Adenoviral vectors
were propagated in 293 cells, purified by CsCI density
centrifugation, dialyzed, and stored in −80°C. Viral particle
titers were determined spectrophotometrically (Mittereder
et al. 1996).
Generation and transduction of donor-matched DC
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy normal donors by density gradient centrifu-
gation and DC prepared by culturing the adherent fraction
with 800 IU/ml granulocyte-macrophage colony stimulat-
ing factor (GM-CSF; Bayer Healthcare, Seattle, WA, USA)
and 63 ng/ml IL-4 (R&D Systems, Minneapolis, MN,
USA) for 5 days at 37°C as previously described
(Kiertscher and Roth 1996). DC were recovered on day 5
and purified by negative depletion using a mAb cocktail
and anti-mouse Ig-conjugated immunomagnetic beads. DC
were either used fresh or aliquoted and cryopreserved in
medium containing 20% AB serum and 10% DMSO. Fresh
or cryopreserved DC that had been thawed and cultured for
8–24 h in complete media containing GM-CSF and IL-4
were transduced with AdV as described previously (Harui
et al. 2006a, b). Briefly, 5.0×10
5 DC suspended in 100 μl
of complete medium were exposed to a suspension of AdV
in phosphate-buffered saline (PBS) containing calcium and
magnesium at a multiplicity of infection (MOI) of 4,000
viral particles/cell. Cultures were incubated for 2 h at 37°C
in a humidified incubator and an additional 800 μlo f
complete media containing GM-CSF and IL-4 was then
added. Human MegaCD40L (200 ng/ml, Alexis Biochem-
icals, Plymouth Meeting, PA, USA) and interferon gamma
(IFN-γ; 100 U/ml, PeproTech, Rocky Hills, NJ, USA) were
added into culture media 24 h later to stimulate a mature
DC phenotype, and cells were incubated for an additional
24 h and harvested.
Reconstitution and vaccination of NSG mice
A combination of T-and B-cells were purified from
PBMC by negative depletion using a mAb cocktail and
anti-mouse Ig-conjugated immunomagnetic beads. Cells
w e r er e s u s p e n d e di nP B Sa n da d m i n i s t e r e dt or e c i p i e n t
NSG mice (10
7 cells/mouse) by intraperitoneal (i.p.)
injection on day 0 of the reconstitution. To adapt
huPBL-NSG mice as a platform for assessing human
antigen-specific T-cell activation, animals were also
administered an i.p. injection on day 0 of 0.5×10
6 DC
that had been generated from the same donor (donor-
matched) (Fig. 1). Monocyte-derived DCs were adminis-
tered as either control DC (which had not been exposed to
AdV in vitro) along with 1×10
9 or 1×10
10 free AdV-GFP
particles, or as DC that had previously been transduced
with the AdV-GFP vector in vitro (DC/AdV-GFP). For
some experiments, animals were administered a second
injection of donor-matched DC that had been prepared
from the same donor (either DC/AdV-GFP or control DC
in combination with free viral particles) 7 days later using
t h es a m em e t h o d s .
Cell recovery and analysis of human cells by flow
cytometry
Single-cell suspensions were prepared from the spleen by
mechanical disaggregation and from the peritoneal cavity by
lavage followed by depletion of red blood cells by hypotonic
shock. Cells were stained with fluorochrome-conjugated
mAbs and analyzed by flow cytometry (FacsCalibur,
Becton-Dickinson, San Jose, CA, USA) in combination with
FCS Express analysis software (DeNovo Software, Los
Angeles, CA, USA). Human cells were defined by expression
of human CD45 and subsets identified by specific marker
expression for T-cell subsets (CD3+/CD4+ or CD3+/CD8+
alone or in combination with GITR, CD127, and/or CD25),
B-cells (CD20), NK cells (CD3-/CD56+), NK-T-like cells
(CD3+/CD56+), or DC (CD11c, CD40, CD86, and/or HLA-
DR).
Detection of antigen-specific T-cell responses
Recovered spleen cells were challenged in vitro with
donor-matched control DC or with DC/AdV-RR5 to
detect responses to adenoviral capsid antigens. Antigen-
specific responses were assessed by intracellular cytokine
stimulation (ICCS), proliferation, or cytokine secretion
a s s a y s .F o rI C C S ,2 × 1 0
6 spleen cells were stimulated
with either control DC or DC/AdV-RR5 at a ratio of 1:10
(DC/spleen cells ratio) in complete media in the presence
of 3 µg/ml anti-CD28 Ab (BD Biosciences) and 1 ng/ml
IL-12 (PeproTech) for 5 h at 37°C. Brefeldin A (Sigma-
Aldrich, St. Louis, MO, USA) was added at 10 µg/ml after
the first hour. At the end of the culture period, cells were
fixed and cryopreserved. Intracellular staining for IFN-γ
and tumor necrosis factor alpha (TNF-α) was then carried
out according to the manufacturer’sp r o t o c o l( B D
Biosciences) in combination with counterstaining using
fluorochrome-conjugated anti-CD3, anti-CD4, and anti-
CD8 antibodies. A minimum of 150,000 CD3+ cell events
were analyzed by multi-color flow cytometry. For prolif-
eration assays, spleen cells were first labeled with CFSE
(0.5 µM) and then 2×10
5 cells/well co-cultured with
e i t h e rc o n t r o lD Co rD C / A d V - R R 5a tar a t i oo f1 : 2 0( D C /
spleen cells ratio) in the presence of low dose IL-2 (10 U/
150 J Neuroimmune Pharmacol (2011) 6:148–157ml) and IL-7 (1 ng/ml). Cells were harvested 5 days later,
counterstained with fluorescent-conjugated mAb to indi-
cated markers and analyzed by flow cytometry. Antigen-
specific cytokine secretion was assessed by collecting
supernatants from the same wells used for proliferation
assays and the levels of human IFN-γ and TNF-α
measured by SearchLight multiplex assay (Thermo Scien-
tific, Rockford, IL, USA).
In vivo cytokine production
Serum samples were collected from animals at the time
of spleen recovery and assayed for the presence of
human IFN-γ and TNF-α to determine whether
reconstitution with control DC versus DC/AdV-GFP
resulted in detectable differences in systemic cytokine
levels, reflecting the in vivo activation of antigen-
specific T-cells.
Statistical analysis
Comparisons between groups were performed using Stu-
dent’s t test, with p<0.05 accepted as a significant
difference between groups. All experiments were per-
formed with replicates and results from at least three
separate experiments were pooled for statistical analysis.
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Fig. 1 Reconstitution of huPBL-NSG mice with both PBL and donor-
matched dendritic cells. a Six- to 8-week-old NSG mice were
implanted with 10
7 purified human T-and B-cells (PBL) by i.p.
injection. In order to restore antigen-presenting activity, animals were
also administered donor-matched monocyte-derived DC alone or in
combination with adenoviral antigens (as either DC/AdV-GFP or
control DC + free AdV-GFP particles) by i.p. injection. In some
experiments, animals received a single administration of 5×10
5 DC
and in other experiments they received a second dose of DC 7 days
later. Spleens, peritoneal cells, and serum were recovered on day 14 or
21 for assessment of antigen-specific immune responses. b Purified
human PBL used for implantation into NSG mouse were composed of
subsets of T-cells (CD3+/CD4+, CD3+/CD8+, and CD3+/CD56+) and
B-cells. c Monocyte-derived DC generated from the same donor
express high levels of antigen and maturation markers. DC were
transduced with AdV-GFP at an MOI of 4,000 viral particles/cell and
were stained with antibodies against DC phenotype/maturation
markers including CD11c, HLA-DR, and CD86 48 h later. Flow
cytometry demonstrated a uniform population of DC by forward
scatter (FSC) and side scatter (SSC). The percentage of GFP-positive
cells was used to measure the percentage of DC expressing AdV
antigens after transduction. The fluorescent profile of unstained DC is
presented in gray and fluorescent staining for specific markers are
depicted by black histogram curves. Representative experiment, n=5
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Reconstitution of huPBL-NSG mice with both PBL
and donor-matched dendritic cells
To adapt huPBL-NSG mice as a platform for assessing
human antigen-specific T-cell activation, animals were
implanted with an i.p. injection of 10
7 human PBL and
then supplemented with 0.5–1.0×10
6 DC that had been
generated from the same donor (donor-matched) as detailed
in Fig. 1. Donor PBL were composed primarily of CD3+ T-
cells with a normal complement of CD4 and CD8 subsets, a
population of CD3+/CD56+ cells, and CD20+ B-cells
(Fig. 1b). Culture of adherent PBMC from the same donor
with GM-CSF and IL-4, followed by immunomagnetic
depletion of contaminating lymphocytes, resulted in a
relatively pure and homogenous population of DC
(Fig. 1c). DC prepared in this manner were highly
susceptible to transduction by AdV and expressed high
levels of the characteristic CD11c marker, MHC molecules
(HLA-DR), and costimulatory molecules (such as CD86)
required for efficient T-cell activation.
Immune reconstitution of NSG mice with these two
populations was associated with a marked migration to, and
expansion of, human cells populating the spleen over the
first 2–3 weeks. Splenic repopulation was associated with a
concomitant decrease in the number of intraperitoneal cells
(Fig. 2a). By the end of 3 weeks, the average yield of
human cells from the spleen was 19.4±6.7×10
6 CD45+
cells and the number of residual CD45+ cells in the
peritoneum had decreased to 1.9±0.6×10
6. After 14 days,
78.1±3.0% (n=3) of recovered spleen cells expressed
human CD45 and the percentage of human cells remained
relatively constant through 21 days (Fig. 2b).
Recovered spleen cells contained a distribution of
lymphocyte subsets similar to that of normal human blood
including CD3+/CD4+, CD3+/CD8+, and CD3+/CD56+ T-
cells along with a small population of B-cells (CD20+)
(Fig. 3a). The CD4/CD8 ratio averaged 1.63:1 (n=15) and
there was a direct relationship between the frequency of
CD3+/CD56+ T-cells in the PBL used for implantation and
those covered from the spleen 2–3 weeks later (r
2=0.85,
p<0.01). There was little evidence for T-cell activation as
measured by the expression of either CD25 or CD69 (data
not shown). The i.p. administration of mature monocyte-
derived DC into huPBL-NSG mice also resulted in their
migration and repopulation of the spleen by the end of
2 weeks. Similar to the mature phenotype of these cells at
the time of administration, the majority of recovered
CD11c+ splenic DC expressed high levels of HLA-DR
a n dC D 8 6( > 7 0 % )( F i g .3b). huPBL-NSG mice recon-
stituted in this manner exhibited no physical signs of graft
versus host disease.
Activation of antigen-specific T-cells in vivo
The capacity for human DC derived from the same donor
to interact with and stimulate antigen-specific T-cells in
vivo in huPBL-NSG animals was evaluated under two
different conditions. In the first approach, animals were
administered DC in combination with free AdV-GFP
particles. In the second approach, animals were adminis-
tered DC that had been loaded 48 h earlier with AdV
capsid antigens in vitro. In both settings, the stimulation
of memory T-cell responses to AdV capsid antigens was
assessed by a standard 5-h ICCS assay in which non-
specific T-cell activation was assessed by challenging
recovered cells with control DC (containing no antigen)
while AdV-specific T-cell immunization was assessed by
challenging with DC that had been loaded with the
AdV/RR5 vector. Figure 4 demonstrates the results from
a typical experiment. The baseline frequency of AdV-
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Fig. 2 Engraftment of NSG mice with human PBL. Six- to 8-week-
old NSG mice were implanted with 10
7 purified human T-and B-cells
(PBL) by i.p. injection. Spleen and peritoneal cells were recovered
after 14 or 21 days, counted, and stained with anti-human CD45 mAb
for analysis by flow cytometry. a The increase in human CD45+
leukocytes within the spleen from 14 to 21 days was associated with a
concomitant decrease in peritoneal cell number, suggesting a
combined redistribution and expansion of human cells following i.p.
implantation. b Representative dot-plots demonstrating the percentage
of recovered cells from the spleen and peritoneum that expressed
human CD45 at day 14. Average percentage of human CD45+ cells in
the spleen at day 14 was 78.1±3.0%, n=3
152 J Neuroimmune Pharmacol (2011) 6:148–157specific T-cells capable of producing IFN-γ and TNF-α
before implantation was measured at 0.10% of CD4+ T-
cells (all reported frequencies adjusted for the response to
control DC) and 0.03% of CD8+ T-cells (Fig. 4a). When
PBL were administered to NSG mice in the absence of
DC, the frequency of AdV-specific CD4+ T-cells recov-
ered from day 21 spleen cells was always less than 0.02%
(data not shown). However, huPBL-NSG mice that were
a Lymphocyte Subsets
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Fig. 3 Lymphocyte and DC phenotypes reconstituting the spleens of
huPBL-NSG mice. a Six- to 8-week-old NSG mice were implanted
with 10
7 purified human PBL at day 0 in combination with 5×10
5
donor-matched monocyte-derived DC by i.p injection at day 0 and
day 7. Spleens were recovered 14 days later and cells expressing
human CD45 analyzed by flow cytometry. CD3+ T-cells exhibited a
normal distribution of CD4+ and CD8+ subsets (left); a small
population of B-cells was identified by their expression of CD20
(right); and NK-T-like cells were identified by their expression of
CD56 alone or in combination with CD3, respectively (center).
Representative experiment, n=15. b Six- to 8-week-old NSG mice
were implanted with 10
7 purified human PBL at day 0 and 5×10
5
donor-matched monocyte-derived DC by i.p injection at day 7.
Spleens were recovered 14 days later and DC were identified by
gating on the population of cells expressing CD11c and analyzing the
CD11c+ subset for their expression of both HLA-DR and CD40 (left,
gated for CD45+/CD11c+ cells) and both HLA-DR and CD86 (right,
gated for CD45+/CD11c+ cells). Representative experiment, n=5
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Fig. 4 Donor-matched DC loaded with AdV antigens stimulate
antigen-specific T-cell responses in vitro and in vivo in huPBL-NSG
mice. Adherent PBMC were cultured with GM-CSF and IL-4 for
5 days, transduced with 4,000 MOI AdV-GFP (DC/AdV-GFP), with
4,000 MOI AdV-RR5 (DC/AdV-RR5), or cultured in transduction
medium alone (control DC), and then matured with MegaCD40L and
IFN-γ. a The capacity to stimulate antigen-specific T-cells in vitro
was assessed by co-culturing DC/AdV-GFP with purified donor-
matched T-cells (DC/T ratio=1:20) for 7 days followed by challenge
with either control DC or DC/AdV-RR5 to detect AdV-specific T-cell
frequency in a standard 5-h ICCS assay. Frequencies of antigen-
specific CD4+ and CD8+ T-cells expressing IFN-γ and/or TNF-α are
noted, respectively (all frequencies are adjusted for the background
response to control DC in the absence of antigen). Representative
experiment, n=3. b, c The capacity for DC to stimulate antigen-
specific T-cells in vivo in huPBL-NSG mice was similarly assessed by
immunizing animals with either b 5×10
5 DC/AdV-GFP (on day 7) or
with c 5×10
5 control DC (on day 7) in combination with 2×10
9 free
AdV-GFP particles. Spleen cells were harvested 14 days later and
challenged in vitro with either control DC or DC/AdV-RR5 to detect
AdV-specific T-cell frequency in a standard 5-h ICCS assay.
Frequencies of antigen-specific CD4+ and CD8+ T-cells expressing
IFN-γ and/or TNF-α are noted, respectively. Representative experi-
ment, n=4
J Neuroimmune Pharmacol (2011) 6:148–157 153immunized in vivo with the combination of DC and free
AdV particles exhibited an AdV-specific CD4+ T-cell
frequency of 0.14% (Fig. 4b). Furthermore, when huPBL-
NSG mice were immunized in vivo with DC/AdV-GFP,
the frequency of AdV-specific CD4+ T-cells increased
markedly to 0.39% (Fig. 4c). In replicate experiments, the
AdV-specific CD4+ T-cell responses in animals that were
immunized with DC/AdV-GFP were always greater than
the responses in animals that received control DC in
combination with free AdV-GFP. When administering free
AdV-GFP, the response to 10
10 viral particles (shown in
Fig. 4b) was generally greater than the response to
10
9 viral particles (data not shown).
Antigen-specific cytokine production induced by DC-based
immunization
Sera from immunized huPBL-NSG mice were tested for the
presence of human IFN-γ and TNF-α (Fig. 5). Compared
to serum from control animals that were immunized with
DC alone (no AdV exposure), serum from animals
immunized with DC/AdV-GFP demonstrated consistently
increased levels of both cytokines consistent with the
responses measured in the ICCS assay.
Antigen-specific T-cells generated by immunization
of huPBL-NSG mice respond to a secondary
in vitro challenge
To further evaluate the function of antigen-specific T-cells
that were activated in vivo, spleen cells were recovered
from huPBL-NSG mice that were immunized with
DC/AdV-GFP. The cells were labeled with CFSE and re-
challenged in vitro for 5 days with either control DC
(containing no antigens) or with DC/AdV-RR5 (Fig. 6).
Although some background proliferation was observed in
response to control DC, there was a clear antigen-specific
increase in the percentage of proliferating CD4+ and
CD4− T-cells in response to challenge with DC/AdV-RR5
(Fig. 6a). Further phenotyping of the proliferating cells
revealed that they expressed CD45RO, a memory cell
marker, and that a significant percentage expressed CD25,
an activation marker, in the absence of GITR, suggesting
that they were not suppressor cells (Fig. 6b). Consistent
with the expansion of effector/memory T-cells, supernatant
collected from these co-cultures demonstrated antigen-
specific induction of IFN-γ and TNF-α (Fig. 6c).
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Fig. 5 In vivo cytokine response to DC/AdV-GFP. Sera from huPBL-
NSG mice were collected 14 days after immunization with either
control DC or DC/AdV-GFP and assayed for human IFN-γ and TNF-
α by SearchLight multiplex assay. Representative experiment, n=3.
†p<0.10; *p≤0.05
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Fig. 6 T-cells recovered from immunized huPBL-NSG mice respond
to antigen-specific stimulation in vitro. Spleen cells recovered from
huPBL-NSG mice that were previously immunized with DC/AdV-
GFP in vivo were labeled with CFSE and co-cultured with either
control DC or DC/AdV-RR5 (DC/T ratio=1:20) for 5 days in vitro. a
Cells were stained with anti-CD3 and anti-CD4 and the CD3+ T-cells
analyzed for adenoviral-specific proliferative responses by flow
cytometry. Representative experiment, n=5. b The sub-population of
cells proliferating in response to stimulation with DC/AdV-RR5
(CFSE-dim) were further analyzed for their expression of effector/
memory and regulatory T-cell markers. c Supernatants from the same
wells were harvested and assessed for the presence of human IFN-γ
and TNF-α by SearchLight multiplex assay. Representative experi-
ment, n=3. *p<0.01
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Fundamental differences between the mouse and human
immune systems, differences in genetic diversity, as well as
inherent differences in the susceptibility and exposure to
human disease, often limit the translational potential of mouse
models for developing effective treatments for human disease.
Avariety of “humanized” animal models have been developed
to address these issues by either expressing human genes/traits
in animals (Pascolo et al. 1997;M a n g a l a me ta l .2008;
Conforti et al. 2009) or by engrafting human immune cells
into immunodeficient mice (Mosier et al. 1988; Ito et al.
2002; Ishikawa et al. 2005). However, one significant
limitation has been the study of adaptive immunity. The
huPBL-NSG model provides a unique opportunity to study
the interaction of various immune challenges with human
immune cells (Kumar et al. 2008; Strowig et al. 2009; King
et al. 2009). We herein demonstrate that the addition of
donor-matched monocyte-derived DC to the reconstitution of
huPBL-NSG animals enabled us to rapidly assess and
stimulate the donor’s antigen-specific memory in vivo, in
the intact animal, as well as ex vivo, after recovery of spleen
cells from immunized animals.
Our results confirm that rapid reconstitution of the
spleen and peripheral blood occurs following a single i.p.
injection of human PBL. Within a few weeks, 15–25
million human cells can be recovered from the spleen with
the CD3+/CD4+, CD3+/CD8+, CD3+/CD56+, and CD20+
populations all well represented in appropriate proportions.
Regardless of whether administered only once (at day 0 or
7) or twice (at both day 0 and 7), implanted DC were
detected at low levels in the spleen and expressed the
phenotypic markers of functional antigen-presenting cells.
Importantly, reconstitution with DC did not lead to physical
signs of GVHD or to changes in the level of acute
activation markers (CD25 and CD69; data not shown).
However, reconstitution with DC did enable the huPBL-
NSG animals to respond to antigen challenge. Adenovirus
was chosen as the target antigen for this work due to its
well-characterized immunogenicity in humans and the
presence of highly sensitive assays for assessing AdV-
specific T-cell responses (Roth et al. 2002). Similar to the
response pattern observed in vivo when humans are
immunized with AdV (Gahéry-Ségard et al. 1997), fully
reconstituted huPBL-NSG animals rapidly expanded the
population of AdV-specific T-cells following exposure to
AdV. In the absence of an antigen challenge, essentially no
detectable AdV-specific T-cells were detected in freshly
harvested splenocytes. However, following active immuni-
zation with DC/AdV-GFP, there was a dramatic upregula-
tion of AdV-specific T-cells that far exceeded the level
detected when the original donor PBL were stimulated in
vitro for a week with IL-2, IL-7, and DC/AdV-GFP. As
might be expected when healthy patients are immunized
with a vaccine, immunization of the intact animal was more
effective than standard in vitro stimulation. While a cell-
based vaccination (DC/AdV-GFP) elicited the greatest in
vivo response, administration of free AdV-GFP vector also
stimulated an AdV-specific T-cell response. In this case, the
magnitude of the response appeared to increase with the
quantity of antigen administered.
In addition to the in vivo expansion of antigen-specific
T-cells, immunization of huPBL-NSG animals with DC/
AdV-GFP induced the systemic release of IFN-γ and TNF-
α into the serum. The detection of these circulating
cytokines was a robust indicator of the AdV-specific T-
cell response and consistent with reports that IFN-γ and
TNF-α represent the predominant T-cell cytokines pro-
duced upon AdV challenge (Hutnick et al. 2010). It is
noteworthy that resting cytokine levels for IFN-γ and TNF-
α were low in unchallenged animals, arguing against the
presence of spontaneous responses to endogenous mouse
antigens.
One advantage of the huPBL-NSG mouse compared to
its NOD/SCID precursors is the robust repopulation of the
spleen with human cells. Harvesting spleens from these
animals provides an abundant source of T-cells for in vitro
analysis. As occurs when human T-cells are recovered from
the blood of healthy subjects, the T-cells recovered from the
spleens of immunized animals were able to undergo further
expansion and testing when stimulated with AdV for
another 5–7 days in vitro. Labeling recovered spleen cells
with CFSE allowed us to track the proliferative response to
a secondary in vitro challenge with DC/AdV-RR5 and to
characterize the phenotype of responding cells. Interesting-
ly, this was the one situation in which there was a
significant background response when the cells were
stimulated with control DC that had not been loaded with
AdV. As the co-cultures contained up to 30% mouse cells
recovered from the spleen, it seems likely that uptake and
processing of these cells by the added DC lead to an in vitro
anti-mouse response. However, despite this higher back-
ground proliferation, challenging in vitro with DC/AdV-
RR5 still led to a significantly greater response than did
challenging with control DC alone. T-cells proliferating in
response to DC/AdV-RR5 were mostly CD45RO+ cells and
approximately 25% of them expressed moderate levels of
CD25 without expression of GITR, suggesting the presence
of memory/effector T-cells, but not T-regulatory cells. This
would be expected given our use of mature DC to
immunize the animals in vivo (Roth et al. 2002; Harui et
al. 2004). As detected in serum collected from immunized
animals, IFN-γ and TNF-α were secreted into the culture
supernatant during the in vitro challenge.
In summary, these findings support our hypothesis that
reconstitution of NSG mice with a combination of human
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huPBL-NSG model in which adaptive T-cell responses can
be stimulated and measured in the intact animal. There are
several potential advantages of this model over others that
have been reported in the literature. Gorantla et al. (2005)
reported that NOD/SCID animals can be treated with
asialo-GM1 and anti-CD122 antibodies to aid human
engraftment and then vaccinated with antigen-loaded DC.
While providing an important proof of concept, the use of
NOD/SCID animals for this purpose has been replaced by
newer animal strains due to the large number of cells
required and the very limited engraftment that is obtained
(Shultz et al. 2000; Shultz et al. 2003). Conventional
engraftment of NSG mice with CD34+ stem cells is limited
by the failure of normal T-cell development and the lack of
pre-existing immune memory (Ishikawa et al. 2005). Yu et
al. (2008) overcame these limitations by transplanting
NOD/SCID β2 microglobulin
−/
− mice with peripheral
blood CD34+ stem cells (3×10
6/animal) to promote DC
and B-cell repopulation followed by supplementation
4–8 weeks later with donor-matched PBL as the source of
T-cell responders. While requiring a leukopheresis to obtain
sufficient CD34 donor cells, whole-body irradiation in
combination with a 10-day course of human FLT3 ligand to
promote engraftment, and then a protracted period for
reconstitution, the resulting humanized animals responded
well to both live influenza virus and inactivated influenza
vaccine. As in our model, they observed a significant in
vivo expansion of memory/effector T-cells with defined
antigen specificity and cytokine production. Also similar
to our work, they demonstrated that DC were crucial for
the generation of an antigen-specific response. While
based on similar principals, our model allows reconstitu-
tion from a single peripheral blood draw, and animals are
ready for immunologic testing in as little as 2 weeks
without further manipulation. In addition, these animals
are stable for at least 6 weeks after implantation of human
PBL. The large number of human cells that can be
recovered from the spleen facilitates the extensive in vitro
analysis that is often required when mapping out T-cell
responses. Altogether, this model provides a highly
adaptable platform to study the interaction of antigen
presentation and antigen-specific T-cell responses in vivo.
Immunologic responses to a variety of viruses can likely
be studied using these approaches, new vaccines tested
without the need to administer them to human subjects,
and a variety of drugs and immune modulators evaluated
for their impact on various stages of antigen presentation
and T-cell function.
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